Join 2 text

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Results from the NIRVANA-R trial found niraparib/bevacizumab maintenance yielded positive activity in pretreated ovarian cancer.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Kathleen N. Moore, MD, MS

Uterine Cancer Survival Rates Have Improved Despite Higher Mortality Risks

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.

Russ Conroy

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

March 10th 2025

Pelabresib Plus Ruxolitinib Improves Spleen Responses in Myelofibrosis

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.

Modakafusp Alfa Exhibits Antitumor Activity, Immune Activation in Myeloma

The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.

Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer

Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

Related Content

Ariana Pelosci

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Results from the NIRVANA-R trial found niraparib/bevacizumab maintenance yielded positive activity in pretreated ovarian cancer.

Kathleen N. Moore, MD, MS

Uterine Cancer Survival Rates Have Improved Despite Higher Mortality Risks

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Russ Conroy

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

March 10th 2025

Pelabresib Plus Ruxolitinib Improves Spleen Responses in Myelofibrosis

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Modakafusp Alfa Exhibits Antitumor Activity, Immune Activation in Myeloma

The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.